Table 2.
OS | RFS | |||||
---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | |
biCEBPA versus moCEBPA (univariable analysis) | 0.4 | 0.2-0.8 | 0.008 | 0.5 | 0.2-0.9 | 0.021 |
biCEBPA versus moCEBPA (adjusted for FLT3-ITD) | 0.4 | 0.2-0.8 | 0.006 | 0.5 | 0.2-0.9 | 0.021 |
biCEBPA versus moCEBPA (adjusted for FLT3-TKD) | 0.4 | 0.2-0.8 | 0.012 | 0.4 | 0.2-0.9 | 0.018 |
biCEBPA versus moCEBPA (adjusted for FLT3-ITD and FLT3-TKD) | 0.4 | 0.2-0.8 | 0.006 | 0.4 | 0.2-0.8 | 0.012 |
biCEBPA versus moCEBPA (adjusted for FLT3-ITD, NPM1 mutations and interaction NPM1/FLT3-ITD) | 0.2 | 0.1-0.5 | <0.001 | 0.2 | 0.1-0.6 | 0.003 |
biCEBPA versus moCEBPA (adjusted for NPM1 mutations) | 0.2 | 0.1-0.5 | <0.001 | 0.2 | 0.1-0.6 | 0.002 |
biCEBPA versus moCEBPA (adjusted for PINAOS or PINARFS (both without biCEBPA)) | 0.2 | 0.1-0.4 | <0.001 | 0.2 | 0.1-0.6 | 0.001 |
Abbreviations: biCEBPA biallelic mutation in the CCAAT/enhancer-binding protein alpha, CI confidence interval, FLT3-ITD internal tandem duplication of the FLT3 gene, FLT3-TKD mutation in the tyrosine kinase domain of the FLT3 gene, HR hazard ratio, interaction NPM1/FLT3-ITD, NPM1 positive/FLT3-ITD positive versus NPM1 negative or FLT3-ITD negative, moCEBPA monoallelic mutation in the CCAAT/enhancer-binding protein alpha, NPM1, nucleophosmin gene, OS Overall survival, p p value, PINA OS Prognostic Index for OS in cytogenetically normal AML [29], PINA RFS Prognostic Index for RFS in cytogenetically normal AML [29], RFS Relapse-free survival.